Human Patents (Class 435/366)
  • Patent number: 11093787
    Abstract: Methods, apparatuses, systems, and implementations for creating 3-dimensional (3D) representations exhibiting geometric and surface characteristics of brain lesions are disclosed. 2D and/or 3D MRI images of the brain may be acquired. Brain lesions and other abnormalities may be identified and isolated with each lesion serving as a region of interest (ROI). Saved ROI may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D brain lesion images may be used to create 3D printed models of the isolated brain lesions using 3D printing technology. Analysis of the 3D brain lesion images and the 3D printed brain lesion models may enable a more efficient and accurate way of determining brain lesion etiologies.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 17, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Darin T Okuda, Braeden D Newton
  • Patent number: 11015171
    Abstract: The purpose of the present invention is to provide immortalized stem cells for producing culture supernatant that can be used in the treatment of human diseases. Provided is a method for producing immortalized stem cells, the method being provided with: a step for producing a DNA fragment that includes a telomerase reverse transcriptase and at least one gene selected from the group consisting of Bmi-1, human papilloma virus E6, and human papilloma virus E7; a step for producing a viral vector that incorporates the DNA fragment including the gene; a step for transfecting the viral vector into mammalian stem cells and introducing the gene into the stem cells; and a step for culturing the stem cells into which the gene was introduced and using a drug to select immortalized stem cells.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: May 25, 2021
    Assignee: QUARRYMEN & Co. Inc.
    Inventor: Yasuhiro Yamashita
  • Patent number: 11001802
    Abstract: The present invention relates to the field of mammalian cell culture, and provides methods and compositions for cell attachment to, cultivation on and detachment from a solid substrate surface containing from at least about 0.5% N, a sum of O and N of greater than or equal to 17.2% and a contact angle of at least about 13.9 degrees, lacking a feeder cell layer and lacking an adlayer. In one embodiment of the present invention, the cells are treated with a compound capable of inhibiting Rho kinase activity. In another embodiment, the cells are treated with a compound capable of inhibiting Rho activity.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 11, 2021
    Assignee: Nunc A/S
    Inventors: Benjamin Fryer, Shelley Nelson, Villy Nielsen, Tina Kristensen Marwood, Thomas Brevig
  • Patent number: 10988518
    Abstract: The present invention provides a method for producing a ? myosin heavy chain in cardiac muscle cells differentiated from induced pluripotent stem cells derived from Homo sapiens. In the present method, first, a liquid culture medium containing the cardiac muscle cells is supplied onto a substrate comprising a first electrode, a second electrode and insulative fibers on the surface thereof. At least a part of the insulative fibers is located between the first electrode and the second electrode in a top view of the substrate. Then, the substrate is left at rest. Finally, the cardiac muscle cells are cultivated, while a pulse electric current is applied to the cardiac muscle cells through the first electrode and the second electrode.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 27, 2021
    Assignee: PANASONIC CORPORATION
    Inventors: Kiyotaka Tsuji, Li Liu
  • Patent number: 10982213
    Abstract: The present invention discloses an siRNA that inhibits K-RAS gene expression, and the precursor sequences and applications thereof. The K-RAS siRNA and its precursor sequences provided by the present invention can efficiently inhibit the expression of the K-RAS gene, and in vivo experiments have shown that the K-RAS siRNA has a certain inhibitory effect on tumours highly expressing K-RAS. The precursor of the siRNA of the invention and its vector can form a stable siRNA that functions in a host.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 20, 2021
    Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.
    Inventors: Chenyu Zhang, Xi Chen, Hongwei Liang, Uzair Ur-Rehman, Ke Zeng
  • Patent number: 10968429
    Abstract: Culture media, which contain chelated iron, promote cell proliferation of neural stem cells and/or neural progenitor cells while maintaining undifferentiated state and multipotency.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 6, 2021
    Assignee: AJINOMOTO CO., INC.
    Inventors: Takuya Matsumoto, Sho Senda, Tsuyoshi Kobayashi, Akihiro Arakawa
  • Patent number: 10968435
    Abstract: The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: April 6, 2021
    Assignee: New York Stem Cell Foundation, Inc.
    Inventors: Scott Noggle, Kevin C. Eggan, Stephen Chang, Susan L. Solomon
  • Patent number: 10953048
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: March 23, 2021
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory Alan Bird
  • Patent number: 10947502
    Abstract: Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 16, 2021
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Maksym A. Vodyanyk, Xin Zhang, Andrew J. Brandl, Deepika Rajesh, Bradley Swanson, Christie Munn, Sarah A. Burton, Wen Bo Wang
  • Patent number: 10947490
    Abstract: A liquid delivery device includes a first and second container for a first and second liquid; a third container for receiving a first and second liquid; a fourth container into which a first and second liquid are discharged; a fifth container for a third liquid; a first liquid delivery tube for delivering a first liquid; a second liquid delivery tube for delivering a second liquid; a third liquid delivery tube connected to the first and second liquid delivery tube; a first liquid delivery pump on the third liquid delivery tube; a fourth liquid delivery tube for discharging a first liquid contained in the third container and delivering a third liquid to the third container; a fifth liquid delivery tube connected to the fourth liquid delivery tube; a sixth liquid delivery tube connected to the fourth liquid delivery tube; and a second liquid delivery pump on the fourth liquid delivery tube.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 16, 2021
    Assignee: HITACHI, LTD.
    Inventors: Hikaru Saito, Masaharu Kiyama, Midori Kato, Kunio Ohyama, Guangbin Zhou, Hiroko Hanzawa, Shizu Takeda
  • Patent number: 10935542
    Abstract: Variations in the differentiation and lineage potential of stem cells, including mesenchymal stem cells, currently limit their therapeutic use. The ability to identify, isolate, and specifically amplify stem cell populations with desired differentiation potential would contribute the use of stem cells in research and therapy. The present invention discloses a method of assessing differentiation potential of stem cells by measuring the differential expression of antigens CD 146 and NG2 on the stem cells. The correlation between CD 146 and NG2 expression and differentiation and trilineage potential is explored. The invention also discloses methods to specifically amplify or enrich stem cells with desired differentiation potential, monitor the differentiation potential of a heterogeneous stem cell population, quantify the heterogeneity in differentiation potential of a stem cell culture, and remove stem cells with specific differentiation potentials from a heterogeneous cell culture.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: March 2, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND OFFICE OF TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY DEVELOPMENT
    Inventors: Kim O'Connor, Katie Russell
  • Patent number: 10918707
    Abstract: The invention pertains to the use of VirB10 to immunize a host against an infection by a bacterium having T4SS. The invention provides a vaccine comprising VirB10, a fragment of VirB10, a polynucleotide encoding VirB10 or a polynucleotide encoding a fragment of VirB10 and a pharmaceutically acceptable carrier and/or adjuvant. The invention also provides a method of immunizing a host against an infection caused by a bacterium having T4SS, the method comprising administering to the host a vaccine of the invention. The vaccines and the methods of the invention can be used to immunize against infections caused by bacteria having T4SS in dogs, rabbits, cats, pigs, cattle, sheep, goats, deer, horses, rodents and humans.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 16, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Anthony F. Barbet, Francy L. Crosby
  • Patent number: 10913931
    Abstract: A method of preparing viable stromal and mesenchymal stem cells from adipose tissue that produces high quality and high counts of stem cells with a low risk of contamination. The apparatus provides ultrasonic waves through a constant temperature bath to the tissue held in a sterile sonication container such as a test tube or jar. No sonication probe touches the tissue or the cells during the process. The stem cells produced are ready to be administered to a patient.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Inventor: Glenn Polansky
  • Patent number: 10844354
    Abstract: This disclosure generally concerns the fields of cell biology and molecular biology. In particular the invention concerns the field of stem cell biology and maturation of stem cell-derived cardiomyocytes. Disclosed is a method for improving the maturity of stem-cell derived cardiomyocytes, in particular of the ventricular type, as can be witnessed by, for example, an improved upstroke velocity of the stem-cell derived cardiomyocytes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 24, 2020
    Assignee: NCARDIA B.V.
    Inventors: Stefan Robbert Braam, Leon Tertoolen, Christine Mummery
  • Patent number: 10815480
    Abstract: Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: October 27, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Patent number: 10808224
    Abstract: The present invention provides a method of obtaining aggregates containing a rostral hypothalamus tissue and a rostral head ectodermal tissue, a hypophysis precursor tissue and a hypophysis hormone producing cell, by using a serum-free medium (preferably substantially free of growth factor and insulins), forming homogeneous aggregates of stem cells from pluripotent stem cells such as ES cell and the like, which are plated at a high cell concentration, and subjecting the formed aggregates to floating-culture.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: October 20, 2020
    Assignees: RIKEN, Sumitomo Chemical Company, Limited
    Inventors: Yoshiki Sasai, Hidetaka Suga
  • Patent number: 10787640
    Abstract: Methods are provided for the generation of mesodermal cell types and derivatives thereof. Also provided are methods for generating purified populations of mesodermal cell types and derivatives thereof. The instant disclosure also provides methods of screening for cellular responses of the generated mesodermal cell types and derivatives thereof. Also provide are methods for screening for organismal phenotypes induced by introduction of the generated mesodermal cell types and derivatives thereof. Treatment methods making use of the generated mesodermal cell types and derivatives thereof are also provided. The instant disclosure also provides systems, compositions, and kits for practicing the methods of the disclosure.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: September 29, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kyle Ming Loh, Irving L. Weissman, Lay Teng Ang, Angela Chen
  • Patent number: 10774234
    Abstract: The present invention is to provide a cell culture vessel comprising a copolymer which contains a recurring unit containing an organic group of the following formula (a) and a recurring unit containing an organic group of the following formula (b) being coated onto a surface thereof, a method for manufacturing the same and a method for manufacturing a cell aggregate using the same (wherein Ua1, Ua2, Ub1, Ub2 and Ub3, and An? are as defined in the present specification and the claims).
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: September 15, 2020
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Ayako Otani, Taito Nishino, Yoshiomi Hiroi, Takahiro Kishioka, Tomoyuki Ozawa
  • Patent number: 10760048
    Abstract: Methods and systems for generating MGE precursor cells in vitro as well as compositions of enriched MGE precursor cells are provided. The methods and systems provide efficient production of MGE precursors. The methods and systems disclosed herein provide functional MGE precursors which differentiate into functional GABAergic interneurons.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: September 1, 2020
    Assignee: The Regents of the University of California
    Inventors: Cory R. Nicholas, John L. Rubenstein, Arnold R. Kriegstein, Arturo Alvarez-Buylla
  • Patent number: 10760053
    Abstract: The present disclosure provides a method of manufacturing and differentiating mammalian stem cells, and in one embodiment human induced pluripotent stem cells (iPSc), e.g., manufacturing neuron progenitors, e.g., derived from iPSC, on a large scale by the use of an automated hollow fiber reactor system. In one embodiment, human iPSc that can be differentiated into cardiomyocytes or neuron progenitors are provided. The method comprises seeding a hollow fiber reactor with stem cells such as iPSc, or differentiated iPSc, growing and expanding the seeded cells using appropriate growth factors and nutrients, and harvesting the cells after expansion from the hollow fiber reactor walls, e.g., with the use of an enzyme. The method can produce billions of cells per week from seeding the reactor with a minimum number of starting stem cells or neuron progenitor cells.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 1, 2020
    Assignee: StemoniX Inc.
    Inventor: Robert John Petcavich
  • Patent number: 10743996
    Abstract: There are disclosed compositions for achieving reverse phase characteristics, methods of preparation thereof, and the use of amniotic tissue for cartilage repair. In an embodiment, a biocompatible articular tissue repair composition may have a therapeutic material and a carrier configured for achieving reverse phase characteristics, and methods for using the composition. In various embodiments, the therapeutic material may be amniotic tissue. In various embodiments, the carrier may be a poloxamer such as poloxamer 407. Other embodiments are also disclosed.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 18, 2020
    Inventor: Robert L. Bundy
  • Patent number: 10704043
    Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as a GGG. Related methods are also described.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: July 7, 2020
    Assignee: Exicure, Inc.
    Inventors: Weston Daniel, Scott Mix
  • Patent number: 10704025
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: July 7, 2020
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 10655101
    Abstract: Methods of preparing ovarian tissue for primordial follicle growth are presented comprising the steps: providing an ovarian tissue sample comprising cortical tissue and stromal tissue; removing damaged tissue from the ovarian tissue sample where present; removing excess stromal tissue from the ovarian tissue sample where present; and then mechanically stretching the ovarian tissue sample along at least one dimension of the ovarian tissue sample, such that the size of the ovarian tissue sample along the at least one dimension is increased by at least 10%. Methods of growing viable oocyte in vitro, and methods of preparing individual ovarian follicles for growth are also presented.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: May 19, 2020
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Evelyn Elizabeth Telfer, Marie McLaughlin
  • Patent number: 10655100
    Abstract: The present invention relates to a method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation, and more particularly, to a method of promoting the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by stimulating and activating the surface receptor CXCR2 of the embryoid bodies with the CXCR2-specific ligand GRO-?. The method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation according to the present invention can increase the efficiency and utility of stem cells as a cell therapeutic agent, because it promotes the differentiation of stem cells into a specific germ layer serving as the origin of target cells, which is the first important step for inducing the differentiation of stem cells into specific cells.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 19, 2020
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Byung Soo Kim, Ji-Hye Jung, Yong Park
  • Patent number: 10655098
    Abstract: The embodiments of the invention described herein relate to systems and methods for culturing and/or maintaining intestinal cells, tissues and/or organoids in vitro. The cells, tissues and/or organoids cultured according to the methods and systems described herein can mimic or reproduce natural intestinal epithelial structures and behavior as well as support co-culture of intestinal microflora.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: May 19, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Donald E. Ingber, Hyun Jung Kim
  • Patent number: 10633541
    Abstract: A composition for sealing defects in structural materials such as roads or paved surfaces, the composition preferably comprising one or more shape memory polymer (SMP) components capable of responding to increased temperature by decreasing in volume. Smart SMP-based sealants of the invention serve to avoid adhesion failure between a sealant and the repaired structure when the repaired structure is subjected to varied temperatures that cause thermal expansion and contraction.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: April 28, 2020
    Assignee: Board of Supervisors of Louisiana State University Agriculture And Mechanical College
    Inventor: Guoqiang Li
  • Patent number: 10620109
    Abstract: The present invention aims to provide a method of sorting a skeletal muscle progenitor cell from a cell population containing the skeletal muscle progenitor cell. The above-mentioned problem is solved by providing a step of introducing miRNA-responsive mRNA into a cell population. The miRNA-responsive mRNA contains (i) a nucleic acid having a sequence specifically recognized by miRNA specifically expressed in a skeletal muscle progenitor cell, and (ii) a nucleic acid containing a sequence encoding a marker protein.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: April 14, 2020
    Assignee: KYOTO UNIVERSITY
    Inventors: Hirohide Saito, Seiya Takahashi, Hidetoshi Sakurai, Takahiko Sato, Satoru Takayama
  • Patent number: 10604739
    Abstract: Methods and composition for the production of cardiomyocytes from differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including differentiating pluripotent stem cells in a large volume of suspension culture in the presence of ROCK inhibitors are described. In further aspects, methods for differentiation of stem cells into cardiomyocytes that overcome variability between different stem cell clones and different batch of culture medium are provided.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 31, 2020
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Casey Stankewicz, Matt Riley, Nathaniel Beardsley, Wen Bo Wang, Peter Fuhrken, Steven Kattman
  • Patent number: 10583204
    Abstract: The present invention includes methods for transferring a multigenic phenotype to a cell by transfecting, preferably by phototransfection, and locally transfecting a cell or a cellular process with a laser while the cell is bathed in a fluid medium comprising two or more nucleic acids, thereby introducing the nucleic acid into the interior of the cell. Expression of the nucleic acids results in a multigenic phenotype in the tranfected cell.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: March 10, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: James Eberwine, Philip G. Haydon, Jai-Yoon Sul, Hajime Takano, Chia-Wen Kitty Wu, Fanyi Zeng
  • Patent number: 10577575
    Abstract: Embodiments for coating a bioreactor with a reagent are described. The embodiments may provide for changing flow rates, direction of flow, and/or bioreactor rotation to enhance the coating of the bioreactor prior to growing cells in the bioreactor.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: March 3, 2020
    Assignee: Terumo BCT, Inc.
    Inventor: Nathan D. Frank
  • Patent number: 10576105
    Abstract: Compositions of HLA-G+ MSC and methods of using them, including methods of transplanting compositions of HLA-G+ MSC into human recipients, are provided. Also provided are methods of preparing compositions of HLA-G+ MSC, including by treatment with DNA methylation inhibitors.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: March 3, 2020
    Assignee: ESCAPE THERAPEUTICS, INC.
    Inventor: Basil M. Hantash
  • Patent number: 10577573
    Abstract: Embodiments described herein relate to an apparatus for positioning and securing an excised biological tissue specimen for imaging and analysis. In some embodiments, an apparatus includes a sample bag defining an inner volume configured to receive a biological tissue sample, and a sealing member coupled to the sample bag. An imaging window is disposed and configured to be placed in contact with at least a portion of the biological tissue sample, and a positioning member is coupled to the imaging window and is configured to be disposed against the sealing member to substantially seal the inner volume. The positioning member includes a vacuum port disposed and configured to be aligned with a vacuum source to withdraw air from the inner volume of the sample bag.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 3, 2020
    Assignee: PERIMETER MEDICAL IMAGING, INC.
    Inventors: Chao Fan, Elizabeth A. Munro, David Rempel, James Jackson
  • Patent number: 10570362
    Abstract: A transfer device designed to extract an amorphous or semi-solid structure, tissue, or construct from supporting media while maintaining the spatial integrity/organizational architecture thereof. The transfer device can include a controller, an actuator assembly, a plunger, and a needle. The controller can move the transfer device and the plunger independently.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: February 25, 2020
    Assignee: DEKA Products Limited Partnership
    Inventors: Michael C. Tilley, Richard E. Andrews, Dane C. Fawkes
  • Patent number: 10519449
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: December 31, 2019
    Assignee: OliX Pharmaceuticals, Inc.
    Inventors: Dong Ki Lee, Sun Woo Hong, Tae Yeon Lee, Sae-Lo-Oom Lee, Hanna Lee, Dayeon Yu, Ji Eom
  • Patent number: 10502738
    Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 10, 2019
    Assignee: AGEX THERAPEUTICS, INC.
    Inventor: Basil M. Hantash
  • Patent number: 10500306
    Abstract: The tissue construct with viable cells in an extracellular matrix made of fibrin is produced with a special method, in which a matrix material and cells are shaped into a hollow body, in particular a tubular hollow body, by means of a rotational casting method in a hollow mould (1), the method comprising the following steps: (a) introduction of cells of at least one cell type and/or a fibrinogen preparation into the rotating hollow mould (1) with the aid of an applicator (4), said applicator (4) being displaced along the rotational axis during the introduction and step (a) being performed one or more times; (b) continuation of the rotation process until the fibrinogen solidifies into a dimensionally stable matrix, obtaining a primarily solidified tissue construct; (c) removal of the tissue construct from the mould. The construct can also he obtained in a relatively short time from autologous materials.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 10, 2019
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Aper, Mathias Wilhelmi, Axel Haverich
  • Patent number: 10494595
    Abstract: An object is to provide a method of manufacturing a vessel for embryoid body formation excellent in formability of an embryoid body and suitable for optical observation.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 3, 2019
    Assignee: NOF CORPORATION
    Inventors: Tomozumi Noda, Fumio Nakashima, Satoshi Yamada, Nobuyuki Sakamoto
  • Patent number: 10494609
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells and the products related to or resulting from such methods. In particular, the present invention provides an improved method for the formation of pancreatic hormone expressing cells and pancreatic hormone secreting cells. In addition, the present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer and the products related to or resulting from such methods. The present invention also provides methods to promote glucose-stimulated insulin secretion in insulin-producing cells derived from pluripotent stem cells.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: December 3, 2019
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Patent number: 10478525
    Abstract: A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: November 19, 2019
    Assignee: BACTERIN INTERNATIONAL, INC.
    Inventors: Nancy J. Shelby, Steven M. Scott, Benjamin P. Luchsinger, Gregory A. Juda, Kelly R. Kirker, Darrel L. Holmes, Jesus Hernandez
  • Patent number: 10473646
    Abstract: The invention relates to a method of in vitro culturing or expanding human or animal tissue (2, 2?). The method comprises: obtaining a sample of human or animal tissue; downsizing tissue (21, 21?) of the sample; generating an assembly by placing the downsized tissue on a scaffold or hydrogel (22, 22?); arranging the assembly inside a culture chamber of a 3D perfusion system (23, 23?); and perfusing the assembly in the 3D perfusion system for a predefined time (24, 24?). The method according to the invention allows for preparing and directly culturing in vitro fresh tissue specimens for a high efficient in vitro culturing using a perfused bioreactor system.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: November 12, 2019
    Assignees: UNIVERSITAETSSPITAL BASEL, CELLEC BIOTEK AG
    Inventors: Christian Hirt, Adam Papadimitropoulos, Giandomenica Iezzi, Volker Lorber, Manuele Giuseppe Muraro
  • Patent number: 10471097
    Abstract: The present invention relates to hyaluronic acid-rich node and duct system (HAR-NDS)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (NDSCs), which are adult stem cells having an ability to differentiate into HAR-NDS-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from HAR-NDS, adult stem cells NDSCs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: November 12, 2019
    Assignee: Eutilex Co., Ltd.
    Inventor: Byoung Se Kwon
  • Patent number: 10428303
    Abstract: Improved methods of culturing embryos in media having amounts of lactate that have not previously been recognized as beneficial for embryo development. Also, compositions, devices and kits related to the same.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: October 1, 2019
    Assignee: FUJIFILM Irvine Scientific, Inc.
    Inventors: Rebecca Gilbert, Hsiao-Tzu Ni, Suh-Fon Hwan
  • Patent number: 10392600
    Abstract: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. In accordance with the present invention, a selectable marker gene has been recombinantly targeted to the brachyury locus to allow the isolation and characterization of cell populations that comprise brachyury positive mesendoderm and mesoderm cells. The cell populations of the invention are useful for generating cells for cell replacement therapy.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 27, 2019
    Assignee: ICAHN School of Medicine at Mount Sinai
    Inventors: Gordon Keller, Valerie Kouskoff, Atsushi Kubo, Hans J. Fehling
  • Patent number: 10377989
    Abstract: The present invention provides methods of preparing aggregated pluripotent stem cell clusters for differentiation.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: August 13, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Benjamin Fryer, Daina Laniauskas, Marcia Blackmoore, Haiyun Wang, Kostadinka LiLova, Shelley Nelson, Elizabeth Rosocha
  • Patent number: 10370644
    Abstract: The present invention provides methods of preparing aggregated pluripotent stem cell clusters for differentiation. Specifically, the invention discloses methods of differentiating pluripotent cells into beta cell, cardiac cell and neuronal cell lineages using suspension clustering. The methods involve preparing the aggregated cell clusters followed by differentiation of these clusters.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: August 6, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Benjamin Fryer, Daina Laniauskas, Marcia Blackmoore, Haiyun Wang, Kostadinka Lilova, Shelley Nelson, Elizabeth Rosocha
  • Patent number: 10363341
    Abstract: The present invention relates to a tissue-engineered intervertebral disc (IVD) suitable for total disc replacement in a mammal and methods of fabrication. The IVD comprises a nucleus pulposus structure comprising a first population of living cells that secrete a hydrophilic protein and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and type I collagen. The collagen fibrils in the annulus fibrosis structure are circumferentially aligned around the nucleus pulposus region due to cell-mediated contraction in the annulus fibrosis structure. Also disclosed are methods of fabricating tissue-engineered intervertebral discs.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: July 30, 2019
    Assignee: Cornell University
    Inventors: Lawrence J. Bonassar, Roger Hartl, Robert D. Bowles, Harry H. Gebhard
  • Patent number: 10351827
    Abstract: There is provided a method of differentiating an induced pluripotent stem cell (iPSC) into a renal proximal tubular cell (PTC)-like cell. The method comprises culturing an undifferentiated iPSC in a renal epithelial cell culture medium in the presence of one or more extracellular matrix (ECM) molecules, bone morphogenic protein 2 (BMP2) and bone morphogenic protein 7 (BMP7), for a period of from about 8 to about 10 days, under conditions sufficient to induce differentiation of the iPSC into a PTC-like cell. A cell population of differentiated PTC-like cells is also provided, as well as uses and methods of use of the cell population.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 16, 2019
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Daniele Zink, Jackie Y. Ying
  • Patent number: 10337009
    Abstract: The invention provides a single-stranded nucleic acid molecule of (A) or (B) containing a TGF-?1 gene expression inhibitory sequence. The single-stranded nucleic acid molecule (A) consists of region (Xc), linker region (Lx) and region (X) from the 5?-side to the 3?-side, wherein linker region (Lx) has a non-nucleotide structure containing at least one of a pyrrolidine skeleton and a piperidine skeleton, and at least one of region (X) and region (Xc) contains the expression inhibitory sequence.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: July 2, 2019
    Assignee: BONAC CORPORATION
    Inventors: Takahiro Matsumoto, Hidekazu Toyofuku
  • Patent number: 10336980
    Abstract: A portable apparatus useful for collection and processing of human biological material, such as adipose or cancellous bone material, to prepare a concentrated product (e.g., stromal vascular fraction). The apparatus has a container with a containment volume with a tissue retention volume and a filtrate volume separated by a filter and with a pellet well for collecting concentrate product in the form of a pellet phase from centrifuge processing. The pellet well is accessible only from above when the apparatus is in an access orientation. Collected pellet phase material may be removed from the pellet well by direct aspiration, without suspending the material in a suspension liquid within the container. Access ports may be configured for access only from above the container. The apparatus may include a tissue collector disposed in the disuse retention volume to engage and collect collagen or other stringy tissue.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: July 2, 2019
    Assignee: The GID Group, Inc.
    Inventors: William W. Cimino, Ramon Llull, Adam J. Katz